Enhancing Recovery in Early Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 8, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Schizophrenia
Interventions
DRUG

Cannabidiol as add-on

Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks

DRUG

Placebo as add-on

Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks

Trial Locations (6)

10117

RECRUITING

Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte, Berlin

20246

RECRUITING

Department of Psychiatry und Psychotherapy, University Hospital Hamburg-Eppendorf, Hamburg

50924

RECRUITING

Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne, Cologne

52074

RECRUITING

Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen, Aachen

68159

RECRUITING

Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim

80336

NOT_YET_RECRUITING

Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich, Munich

All Listed Sponsors
lead

Central Institute of Mental Health, Mannheim

OTHER